These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33577009)

  • 1. Molecular exploration of combinational therapy of orlistat with metformin prevents the COVID-19 consequences in obese diabetic patients.
    Singh Y; Gupta G; Anand K; Kumar Jha N; Thangavelu L; Kumar Chellappan D; Dua K
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):580-582. PubMed ID: 33577009
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
    Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
    Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early control of diabetic sequelae. Combined insulin treatment also in type 2].
    MMW Fortschr Med; 2000 Jun; 142(25):57. PubMed ID: 10920674
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.
    Maetzel A; Ruof J; Covington M; Wolf A
    Pharmacoeconomics; 2003; 21(7):501-12. PubMed ID: 12696990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women.
    Sari R; Balci MK; Coban E; Yazicioglu G
    Int J Obes Relat Metab Disord; 2004 Aug; 28(8):1059-63. PubMed ID: 15211369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO
    Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effects of current and future anti-obesity drugs.
    Comerma-Steffensen S; Grann M; Andersen CU; Rungby J; Simonsen U
    Curr Vasc Pharmacol; 2014 May; 12(3):493-504. PubMed ID: 24846238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
    Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
    Endocr J; 2010; 57(9):777-86. PubMed ID: 20683173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
    Koiou E; Tziomalos K; Katsikis I; Delkos D; Tsourdi EA; Panidis D
    Hormones (Athens); 2013; 12(4):559-66. PubMed ID: 24457404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of preconceptional orlistat treatment on in-vitro fertilization outcome in overweight/obese women: study protocol for a randomized controlled trial.
    Li J; Wang Z; Wei D; Liu H; Zhang J; Wang J; Shi Y; Chen ZJ
    Trials; 2018 Jul; 19(1):391. PubMed ID: 30021634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An RCT of metformin versus orlistat for the management of obese anovulatory women.
    Metwally M; Amer S; Li TC; Ledger WL
    Hum Reprod; 2009 Apr; 24(4):966-75. PubMed ID: 19095663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin use increases risk of asthma but metformin use reduces the risk in patients with diabetes in a Taiwanese population cohort.
    Chen CZ; Hsu CH; Li CY; Hsiue TR
    J Asthma; 2017 Dec; 54(10):1019-1025. PubMed ID: 28135899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity medications and the treatment of type 2 diabetes.
    Greenway F
    Diabetes Technol Ther; 1999; 1(3):277-87. PubMed ID: 11475274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role.
    Samuel SM; Varghese E; Büsselberg D
    Trends Microbiol; 2021 Oct; 29(10):894-907. PubMed ID: 33785249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of metformin against tuberculosis in diabetic patients.
    Sekhar MS; Unnikrishnan MK; Vyas N
    J Infect Public Health; 2017; 10(2):242-243. PubMed ID: 27262692
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical therapy for the patient with obesity.
    Bray GA; Ryan DH
    Circulation; 2012 Apr; 125(13):1695-703. PubMed ID: 22474312
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis.
    Graff SK; Mario FM; Ziegelmann P; Spritzer PM
    Int J Clin Pract; 2016 Jun; 70(6):450-61. PubMed ID: 27228266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.
    Lamotte M; Annemans L; Lefever A; Nechelput M; Masure J
    Diabetes Care; 2002 Feb; 25(2):303-8. PubMed ID: 11815500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.